{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:43:05Z","timestamp":1791254585667,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":288,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.jhep.2012.06.014","type":"journal-article","created":{"date-parts":[[2012,6,19]],"date-time":"2012-06-19T11:09:25Z","timestamp":1340104165000},"page":"821-829","source":"Crossref","is-referenced-by-count":697,"title":["Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial"],"prefix":"10.1016","volume":"57","author":[{"given":"Jordi","family":"Bruix","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Raoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morris","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Mazzaferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Bolondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Craxi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Galle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Beaugrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Sangiovanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Gerken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge A.","family":"Marrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Nadel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Moscovici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitris","family":"Voliotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M.","family":"Llovet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2012.06.014_b0005","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/jnci\/djn134","article-title":"Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma","volume":"100","author":"Llovet","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jhep.2012.06.014_b0215","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0140-6736(11)61347-0","article-title":"Hepatocellular carcinoma","volume":"379","author":"Forner","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2012.06.014_b0015","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2012.06.014_b0020","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0168-8278(02)00360-4","article-title":"Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy","volume":"38","author":"Imamura","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2012.06.014_b0025","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jhep.2008.01.022","article-title":"Novel advancements in the management of hepatocellular carcinoma in 2008","volume":"48","author":"Llovet","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2012.06.014_b0030","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43\u20139006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2012.06.014_b0035","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd2130","article-title":"Discovery and development of sorafenib: a multikinase inhibitor for treating cancer","volume":"5","author":"Wilhelm","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jhep.2012.06.014_b0040","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/jnci\/djj069","article-title":"BAY 43\u20139006 inhibition of oncogenic RET mutants","volume":"98","author":"Carlomagno","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jhep.2012.06.014_b0045","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2012.06.014_b0050","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2012.06.014_b0055","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers v.2. 2010;2."},{"key":"10.1016\/j.jhep.2012.06.014_b0060","first-page":"311","article-title":"World Gastroenterology Organisation Guidelines and Publication Committee. World Gastroenterology Organisation Guideline (HCC): a global perspective","volume":"19","author":"Ferenci","year":"2010","journal-title":"J Gastrointestin Liver Dis"},{"key":"10.1016\/j.jhep.2012.06.014_b0065","doi-asserted-by":"crossref","first-page":"v59","DOI":"10.1093\/annonc\/mdq166","article-title":"ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Jelic","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2012.06.014_b0070","doi-asserted-by":"crossref","unstructured":"Clinical Practice Guidelines for Hepatocellular Carcinoma \u2013 The Japan Society of Hepatology 2009 update. Hepatol Res 2010;40(Suppl. 1):2\u2013144.","DOI":"10.1111\/j.1872-034X.2010.00650.x"},{"key":"10.1016\/j.jhep.2012.06.014_b0075","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(09)70241-4","article-title":"Asian Oncology Summit. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009","volume":"10","author":"Poon","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2012.06.014_b0080","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1634\/theoncologist.2008-0185","article-title":"Sorafenib for the treatment of unresectable hepatocellular carcinoma","volume":"14","author":"Kane","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.jhep.2012.06.014_b0085","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0885-3924(02)00422-0","article-title":"Assessment of patient-reported clinical outcome in pancreatic and other hepatobiliary cancers: the FACT Hepatobiliary Symptom Index","volume":"24","author":"Yount","year":"2002","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.jhep.2012.06.014_b0090","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/jnci\/djn243","article-title":"REVEAL-HBV Study Group. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma","volume":"100","author":"Yang","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jhep.2012.06.014_b0095","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/hep.21826","article-title":"Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study","volume":"46","author":"Bruno","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2012.06.014_b0100","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/aje\/155.4.323","article-title":"Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women","volume":"155","author":"Donato","year":"2002","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jhep.2012.06.014_b0105","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","article-title":"Hepatocellular carcinoma in cirrhosis: incidence and risk factors","volume":"127","author":"Fattovich","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2012.06.014_b0110","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrc1934","article-title":"Hepatocellular carcinoma pathogenesis: from genes to environment","volume":"6","author":"Farazi","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jhep.2012.06.014_b0115","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1053\/j.gastro.2007.04.061","article-title":"Hepatocellular carcinoma: epidemiology and molecular carcinogenesis","volume":"132","author":"El-Serag","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2012.06.014_b0120","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1055\/s-2007-1007117","article-title":"Epidemiology of primary liver cancer","volume":"19","author":"Bosch","year":"1999","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2012.06.014_b0125","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hep.510290145","article-title":"Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials","volume":"29","author":"Llovet","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2012.06.014_b0130","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1111\/j.1572-0241.2005.00229.x","article-title":"Natural history of untreated nonsurgical hepatocellular carcinoma","volume":"100","author":"Yeung","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2012.06.014_b0135","first-page":"viii168","article-title":"Sorafenib is effective in hepatitis B-positive patients with hepatocellular carcinoma (HCC): subgroup analysis of a randomized, double-blind, phase III trial performed in the Asia-Pacific region","volume":"19","author":"Guan","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2012.06.014_b0140","first-page":"29","article-title":"Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma","author":"Cheng","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2012.06.014_b0145","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1136\/gut.2009.182212","article-title":"New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication","volume":"58","author":"Himmelsbach","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2012.06.014_b0150","article-title":"Antiviral effect of sorafenib in HCV related hepatocellular carcinoma","volume":"54","author":"Cabrera","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2012.06.014_b0155","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/hep.510280322","article-title":"A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients","volume":"28","author":"The Cancer of the Liver Italian Program (CLIP) investigators","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2012.06.014_b0160","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2012.06.014_b0165","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0168-8278(99)80173-1","article-title":"A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d\u2019Etude de la Traitement du Carcinome Hepatocellulaire","volume":"31","author":"Chevret","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2012.06.014_b0170","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1053\/he.2000.5628","article-title":"Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma","volume":"31","author":"The Cancer of the Liver Italian Program (CLIP) investigators","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2012.06.014_b0175","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1200\/JCO.20.6.1527","article-title":"Simplified staging for hepatocellular carcinoma","volume":"20","author":"Vauthey","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2012.06.014_b0180","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1002\/cncr.10384","article-title":"Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients","volume":"94","author":"Leung","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2012.06.014_b0185","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s005350300038","article-title":"Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score)","volume":"38","author":"Kudo","year":"2003","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2012.06.014_b0190","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/j.1440-1746.2004.03350.x","article-title":"Preliminary analysis of a newly proposed prognostic scoring system (SLiDe score) for hepatocellular carcinoma","volume":"19","author":"Omagari","year":"2004","journal-title":"J Gastronterol Hepatol"},{"key":"10.1016\/j.jhep.2012.06.014_b0195","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/j.1440-1746.2004.03538.x","article-title":"Many staging systems for hepatocellular carcinoma: evolution from Child\u2013Pugh, Okuda to SLiDe","volume":"19","author":"Dohmen","year":"2004","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2012.06.014_b0200","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/hep.20636","article-title":"Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort","volume":"41","author":"Marrero","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2012.06.014_b0205","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/hep.23485","article-title":"A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma","volume":"51","author":"Cabibbo","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2012.06.014_b0210","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/bjc.1993.140","article-title":"Performance status assessment in cancer patients. An inter-observer variability study","volume":"67","author":"Sorensen","year":"1993","journal-title":"Br J Cancer"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827812004400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827812004400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,29]],"date-time":"2019-06-29T23:33:08Z","timestamp":1561851188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827812004400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0168827812004400"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2012.06.014","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717952377.793457843","asserted-by":"object"}]},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}